A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

ClinicalTrials.gov ID: NCT03827655

Public ClinicalTrials.gov record NCT03827655. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection

Study identification

NCT ID: NCT03827655
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Takeda; Industry
Enrollment: 209 participants

Conditions and interventions

Conditions

Postoperative Gastrointestinal Dysfunction

Interventions

TAK-954 Placebo Drug
TAK-954 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 6, 2019
Primary completion: May 26, 2022
Completion: May 26, 2022
Last update posted: Jun 22, 2023

2019 – 2022

United States locations

U.S. sites: 19
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
University of South Alabama Medical Center	Mobile	Alabama	30617	—
Keck School of Medicine	Los Angeles	California	90007	—
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
University of California Irvine Medical Center	Orange	California	92868	—
Parkview Community Hospital Medical Center	Riverside	California	92504	—
University of Colorado	Aurora	Colorado	80045	—
University of Miami Leonard M. Miller School of Medicine	Miami	Florida	33136	—
Center for Colon & Rectal Surgery - Altamonte Springs	Orlando	Florida	32804	—
Cleveland Clinic Florida	Weston	Florida	33331	—
Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	46202	—
University of Kentucky	Lexington	Kentucky	40536	—
Ochsner Medical Center	New Orleans	Louisiana	70121	—
University of Massachusetts Memorial Medical Center	Worcester	Massachusetts	01605	—
Stony Brook University Hospital	Stony Brook	New York	11794	—
Fairview Hospital	Cleveland	Ohio	44111	—
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	—
Penn State Health Milton S. Hershey Medical Center	Hershey	Pennsylvania	17033	—
HD Research Corp.	Houston	Texas	77024	—
North Star Medical	Houston	Texas	77089	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03827655, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2023 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03827655 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →